#1 Clinical Trials Search in Europe

Asp1570

Clinical trials are investigating Asp1570 in adults with advanced solid tumors. The studies are looking at safety, tolerability, and the best dose, both when Asp1570 is used alone and when it is combined with pembrolizumab or standard therapies.

Table of Contents

Trial overview

The listed study, NCT05083481, tested Asp1570 in adults with advanced solid tumors.[1] It was an interventional trial, which means the research team assigned treatments and then measured the results.[1]

Who participated

This trial was designed for adults with advanced solid tumors.[1] Advanced solid tumors are cancers made of solid tissue that have grown or spread.[1]

What was tested

The study looked at Asp1570 taken by itself, which is called monotherapy.[1] It also looked at Asp1570 taken together with pembrolizumab, standard therapies, or both.[1] Pembrolizumab is a treatment used in some study groups, and standard therapies are the usual treatments used for the condition.[1]

Study phase and goals

This was a Phase 1/2 trial.[1] Phase 1/2 studies are early trials that first focus on safety and dose, and then help decide whether the treatment plan should be studied further.[1] The brief summary says the study aimed to determine the safety and tolerability of Asp1570 as monotherapy and in combination with pembrolizumab and/or standard therapies.[1] It also aimed to find the RP2D, or recommended Phase 2 dose, and/or the MTD, or maximum tolerated dose.[1]

What was measured

The main outcome was safety variables.[1] These included dose-limiting toxicities, adverse events, changes from baseline in laboratory tests, vital signs, and ECG results.[1] “Baseline” means the starting point before treatment begins.[1] An ECG is a test that records the heart’s electrical activity.[1]

Study status and size

The trial status is listed as completed.[1] It enrolled 310 participants.[1]

Trial ID Phase Condition Studied Status Enrollment
NCT05083481 Phase 1/2 Advanced Solid Tumors Completed 310

FAQ

  • What is being studied in Asp1570 clinical trials? The trials are studying Asp1570 by itself and in combination with pembrolizumab, standard therapies, or both. The main goals are to learn about safety, tolerability, and the best dose.
  • Who can take part in these trials? The trial listed is for adults with advanced solid tumors. Participation depends on the study rules, which decide who can join.
  • What phase are the Asp1570 trials? The study is a Phase 1/2 trial. This means it is an early-stage study that looks at safety first and also explores whether the treatment strategy should move forward.
  • What condition is being studied? The trial is studying advanced solid tumors. Solid tumors are cancers that form a mass in an organ or tissue.
  • What results are the researchers measuring? The main results are safety variables, including dose-limiting toxicities, side effects, lab test changes, vital signs, and ECG changes. The study also looks for the recommended dose and the maximum tolerated dose.

Ongoing Clinical Trials on Asp1570

  • Study of ASP1570 Alone or with Pembrolizumab for Adults with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France Spain

Glossary

  • Advanced solid tumors: Cancers that have grown or spread and are made of solid tissue, not blood cancers.
  • Phase 1/2: An early clinical trial stage. Phase 1 mainly checks safety and dose, while Phase 2 looks more at whether the treatment approach continues to look promising.
  • Monotherapy: Treatment using one study drug alone.
  • Combination therapy: Treatment using the study drug together with another treatment.
  • Pembrolizumab: A treatment used in the trial together with Asp1570 in some study groups.
  • Standard therapies: Usual treatments that are commonly used for a condition.
  • Safety variables: Information used to check whether a treatment is safe, such as side effects and test results.
  • Dose-limiting toxicities (DLTs): Side effects that are serious enough to limit how much of a treatment can be given.
  • Adverse events (AEs): Medical problems or unwanted effects that happen during a study, whether or not they are caused by the treatment.
  • ECG: A test that records the heart's electrical activity.
  • MTD: Maximum tolerated dose. This is the highest dose people can take without too many serious side effects.
  • RP2D: Recommended Phase 2 dose. This is the dose chosen for later studies after early safety testing.

References